SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is trending as a notable decrease in its circulating supply has sparked optimistic community discussions about a potential 'frog cycle' rally for the prominent meme coin. Many holders are actively buying dips and anticipating significant upward momentum, even as some skepticism persists regarding its long-term trajectory.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is trending due to significant ecosystem growth, including a rapidly expanding user base and new integrations with prediction market platforms and perpetual exchanges. The community highlights its advanced parallel EVM architecture and competitive staking yields, driving strong buying interest and long-term conviction even as the broader crypto market faces volatility.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund ($XLE) is trending as heightened geopolitical tensions, particularly around Venezuela and Iran, coupled with stable OPEC+ output, create a "war risk premium" in oil prices. The community is actively discussing the sector's strong outperformance and its role as a key rotational play and potential hedge amidst shifts away from tech-focused investments.

Polygon

Polygon is attracting significant attention following strategic acquisitions that pivot the project into regulated payments and Real-World Assets, driving increased network usage and a token burn. Community sentiment is mixed, with many anticipating a price surge from its technological advancements and new initiatives, even as others express frustration over the token's value lagging behind despite these developments amidst ongoing broader market regulatory discussions.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR is gaining significant attention following news of FedEx joining its Governing Council and the US Military adopting its technology for quantum-secure drones. The community is buzzing with excitement over these major real-world utility adoptions, debating whether the token, known for its enterprise focus and RWA development, is severely undervalued and poised for a breakout amidst broader market fluctuations.

Enbridge, Inc. engages in the provision of gas and oil. It operates through the following segments: Liquid Pipelines, Gas Distribution and Storage, Gas Transmission and Midstream, Renewable Power Generation, and Energy Services. The Liquids Pipelines segment consists of common carrier and contract crude oil, natural gas liquids and refined products pipelines and terminals in Canada and the U.S., including Canadian Mainline, Regional Oil Sands System, Southern Lights Pipeline, Spearhead Pipeline, Seaway Crude Pipeline interest, and other feeder pipelines. The Gas Distribution & Storage segment consists of natural gas utility operations, the core of which is Enbridge gas, which serves residential, commercial and industrial customers. It also includes natural gas distribution activities in Quebec and an investment in Noverco, which holds a majority interest in a subsidiary entity engaged in distribution and energy transportation primarily in Quebec. The Gas Transmission & Midstream segment consists of investments in natural gas pipelines, processing and green energy projects, the company's commodity marketing businesses, and international activities. The Renewable Power Generation segment consists primarily of investments in wind and solar power generating assets, as well as geothermal, waste heat recovery, and transmission assets. The Energy Services segment consists of businesses in Canada and the United States including logistical services, refinery supply services and the firm's volume commitments on various pipeline systems. The company was founded on April 30, 1949 and is headquartered in Calgary, Canada.

Enbridge Inc

Enbridge is trending amid strong financial results, including continued dividend growth and earnings beats, fueled by recent U.S. gas utility acquisitions and a substantial project backlog. The community is focused on the company's stable, fee-based cash flows and its strategic positioning to capitalize on rising energy demand from areas like AI data centers, alongside ongoing renewable energy developments.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

PYTH is generating significant buzz following its partnership with the U.S. Commerce Department to publish economic data on-chain, fueling community discussion about its role as a leading oracle for Real World Assets and its new token buyback program funded by network revenue.

QuickLogic Corp. operates as a semiconductor company, which designs, markets, and supports primarily Customer Specific Standard Products and secondarily, Field Programmable Gate Arrays, sensor software algorithms, software drivers, associated design software and programming hardware. It develops and markets low power customizable semiconductor and software algorithm solutions that enable customers to differentiate their products by adding new features, extending battery life, becoming more contextually aware and improving the visual experience with their mobile, consumer and enterprise products. The company was founded by John M. Birkner, Andrew K. Chan, and Hua-Thye Chua in 1988 and is headquartered in San Jose, CA.

Quicklogic Corp

QuickLogic is actively discussed for its eFPGA chiplet technology on Intel's advanced 18A process node, a key development for next-generation computing and defense applications, positioning the company for significant future contracts despite some investor caution over past revenue performance.

ProShares Trust - ProShares Short Bitcoin ETF

ProShares Short Bitcoin Strategy ETF

ProShares Short Bitcoin Strategy ETF ($BITI) is trending as community discussion intensifies around alleged ties between Jeffrey Epstein and the cryptocurrency industry, fueling a strong narrative that Bitcoin is a "pedo-currency" or "scam" destined for zero. Traders are actively utilizing $BITI to capitalize on this overwhelmingly bearish sentiment against Bitcoin, viewing it as a vehicle to profit from an anticipated market collapse.

PancakeSwap is an automated market maker (“AMM”) that allows two tokens to be exchanged on the Binance Smart Chain. It is fast, cheap, and allows anyone to participate.

PancakeSwap

PancakeSwap is buzzing due to substantial whale accumulation and strategic expansions to new chains like Monad for liquid staking, alongside its ongoing aggressive deflationary tokenomics. The community is optimistic about its potential as an altcoin leader, driven by recent product innovations and supply reduction efforts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

International ETFs to Watch as Foreign Stock Markets Beat the US

International stocks crushed U.S. markets in 2025, with ETFs such as SPDW and JIVE emerging as top plays on the global shift.

<ul class="summary-bullets"><li>CEO Thomas J. Appio said that the company is “disappointed in the results.”</li><li>The experimental therapy, however, was safe and well-tolerated, the company said.</li><li>Rifaximin is already approved in the U.S. and marketed as Xifaxan.</li></ul>Shares of Bausch Health Companies Inc. (BHC) fell 10% on Friday after the company said that its late-stage program evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with liver cirrhosis failed to meet its primary goal.The clinical program <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bauschhealth.com/news-releases/2026/01-23-2026-124516159">evaluated</a> rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes. The program consisted of two global trials involving more than 1000 patients.Hepatic encephalopathy is a serious brain dysfunction caused by liver failure, where the liver can't remove toxins from the blood, allowing them to build up and affect the brain, causing confusion, personality changes, slurred speech, and lethargy, potentially leading to coma.<h2 class="st-heading-2">Executive Takeaway</h2>CEO Thomas J. Appio said that the company is “disappointed in the results.” The experimental therapy, however, was safe and well-tolerated, the company said.“We are currently reviewing the full dataset to determine potential new development opportunities," he said while adding that the company remains committed to bringing new treatments to patients across hepatology and other therapeutic areas.Rifaximin is already approved in the U.S. and marketed as Xifaxan which is slated to lose exclusivity in 2028. The recent trials were evaluating a new variant of the compound.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BHC stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while retail chatter rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed anticipation for the company’s quarterly report in February, saying the company “lost &nbsp;a &nbsp;Battle but not &nbsp;the &nbsp;war.”<stembedurl>https://www.stocktwits.com/Valmaro/message/642700352</stembedurl>Another user, however, opined that the trial failure is “a serious blow” to the company’s future prospects.<stembedurl>https://www.stocktwits.com/Contrarian_Dan/message/642693387</stembedurl><a href="https://stocktwits.com/symbol/BHC">BHC stock</a> has dropped 24% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-market-share-dives-in-ev-stronghold-california-in-2025-paving-way-for-asian-rivals-growth/cmUCgvWR4X8">Tesla’s Market Share Dives In EV Stronghold California In 2025, Paving Way For Asian Rival’s Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Bausch Health logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

BHC Stock Plummets On Failed Liver Cirrhosis Trial: Retail Says ‘Lost Battle But Not The War’

The failed clinical program evaluated rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes.

Equity

The failed clinical program evaluated rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes.


<ul class="summary-bullets"><li>The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company said.&nbsp;</li><li>It will also result in the shut down of sites in the Netherlands, Switzerland, U.S. and China.</li><li>Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.</li></ul> Galapagos NV (GLPG) on Monday announced that its Board of Directors has decided to initiate the wind-down of the company’s cell therapy activities, sending shares up 6% in Monday’s after hours trading.The company had announced its intent to wind down the activities after a strategic review and sale process in October but had held on acting on it until it completed communicating with work councils in the Belgium and Netherlands. The winding down of the said activities will impact about 365 employees across regions including Europe, the U.S. and China, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/05/3213177/0/en/Galapagos-Announces-Board-Decision-to-Initiate-Wind-Down-of-Cell-Therapy-Activities.html">said</a>.It will also result in the shut down of sites in the Netherlands, Switzerland, the U.S. and China. The U.S. facilities to be shut down include one in Princeton and another in Pittsburgh, the company said. More details about the wind down, including details pertaining to its timeline and costs, will be provided with the company’s full year earnings in February, it added.Galapagos CFO Aaron Cox had said in November that the company expects to be cash flow neutral to positive by the end of 2026 if the wind down is implemented.<h2 class="st-heading-2">Future After Wind Down</h2>On Monday, Galapagos said that the wind-down of the cell therapy activities will position it for longer-term growth. The company will continue to manage its non-cell therapy programs and evaluate all strategic alternatives for GLPG3667, an investigational, oral, selective inhibitor of tyrosine kinase 2, to accelerate its development in dermatomyositis and potentially other severe auto-immune indications, the company said.The company will also consider resuming the partnering process for the drug, it said. Galapagos also added that it will continue to maintain its presence at its headquarters in Belgium as well as its hubs in Chicago and San Francisco.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment about GLPG stayed in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<a href="https://stocktwits.com/symbol/GLPG">GLPG stock</a> has gained 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/toyota-us-sales-rise-8-percent-in-q4/cmxMCZPR4Ri">US Heeds Trump To Buy A Toyota: Japanese Automaker’s US Sales Rise 8% In Q4</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A logo of Galapagos, a European pharmaceutical research company, is pictured outside its facility on June 9, 2020 in Leiden, Netherlands. (Photo by Yuriko Nakao/Getty Images) 

Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Subsequent Workforce Reduction 

The company had announced its intent to wind down the activities after a strategic review and sale process in October.

<ul class="summary-bullets"><li>Baytex Energy announced a target of 3% to 5% annual production growth, targeted to reach about 75,000 boe/d in 2028.&nbsp;</li><li>The company said it plans to return a significant portion of Eagle Ford’s $2.14 billion in sale proceeds to shareholders.&nbsp;</li><li>It appointed Chad E. Lundberg as the President and Chief Operating Officer from Dec. 22, 2025.</li></ul>Baytex Energy Corp. (BTE) is setting the stage for growth in 2026 with a $625 million capital budget and plans to return a significant part of its Eagle Ford sale proceeds to shareholders. Additionally, the announcement of a new leadership signals a shift in priorities for the year ahead.Shares of BTE climbed over 2% in Monday's pre-market trade.<h2 class="st-heading-2">Capital Budget Usage</h2>Baytex Energy announced a capital budget of $550 to $625 million for 2026, a target of 3% to 5% production growth reaching about 75,000 barrels of oil equivalent per day (boe/d) in 2028.The company’s 2026 exploration and development budget aims to generate an average annual production of 67,000 to 69,000 boe/d and is expected to deliver 3% to 5% production growth from 2025 levels.Of this, about 55% of the budget will be allocated to light oil assets, and the remaining 45% to heavy oil assets, the company said. Production in the first quarter (Q1) of 2026 is expected to average 68,000 to 69,000 boe/d, with plans to scale to 70,000 boe/d at the end of the year. The company also plans to bring 91 heavy-oil wells onstream, with 2026 production averaging 43,000 to 44,000 bbl/d.Of the total capital expenses, $50 to $75 million growth capital will be focused on the Pembina Duvernay and northeast Alberta Mannville, $50 million will be directed towards infrastructure investment that will include anchor oil batteries and water infrastructure in the Pembina Duvernay, and gas conservation in Peace River, and another $50 million will go towards exploration and land investments, the company said."Looking ahead, we are targeting 3% to 5% annual production growth while investing in exploration and infrastructure for future development. Supported by our industry-leading net cash balance sheet, we are prioritizing shareholder returns in 2026," Eric T. Greager, Chief Executive Officer of Baytex Energy, said.<h2 class="st-heading-2">Sale Proceeds And Executive Charges</h2>Baytex Energy completed the sale of its U.S. Eagle Ford Assets for $2.14 billion on December 19, and plans to return a significant portion of the proceeds to shareholders.The company also reaffirmed its annual dividend guidance of $0.09 per share, subject to Board of Directors approval.Additionally, the energy company announced that Chad E. Lundberg will take over as President and Chief Operating Officer from Dec. 22, 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BTE stock remained in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1291/159;" src="https://news.stocktwits-cdn.com/Baytex_sentiment_png_47e2fce461.webp" alt="On Stocktwits, retail sentiment around BTE stock remained in the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels at the time of writing." width="1291" height="159"></figure>Shares of BTE have gained over 25% in the past one year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CANADA - 2025/09/17: In this photo illustration, the Baytex Energy Corp. logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Baytex Energy Sets 2026 Capital Spending, Growth Targets – And Names New COO

The company announced a capital budget of up to $625 million for 2026, with 55% allocated to light oil assets and 45% to heavy oil assets.

Retail investors on Stocktwits are optimistic about Genius Group’s pivot and hope to see the same returns as MicroStrategy after the latter pivoted to a Bitcoin-first strategy in 2020. | Source: Pixabay

Why Is Genius Group Stock Rising Today?

Genius Group repurchased its stock on the open market at an average price of $0.90 per share from August 28 to September 11, 2025.

Global Equity ETFs Draw Rising Investor Interest

Global equity funds saw $10.65B inflows as Fed rate cut bets, a weak dollar and diversification needs drive investors abroad.

U.S.-listed shares of Birkenstock Holding were up 3% in premarket trading on Thursday, ahead of the German footwear company's quarterly report before the market opens.Analysts expect its third-quarter revenue to rise 19.3%, similar to the preceding two quarters, according to Kofin data. Investors&nbsp;will be watching for comments on the impact of tariffs, price hikes, supply chain disruptions, and the demand landscape in North America and Europe.Piper Sandler, which reaffirmed its 'Overweight' rating this week, noted that unfavorable foreign exchange rates could pressure the company's reported revenue.Birkenstock, known for its clogs or sandals, is in a notably good position. In May, the company raised its annual profit outlook and authorized a $200 million share buyback. Still,&nbsp;<a href="https://stocktwits.com/symbol/BIRK">BIRK shares</a> are down 11% year-to-date.The stock has gained nearly 6% in the last two sessions, and the latest retail sentiment reading on Stocktwits is ‘extremely bullish,’ signaling investor optimism.<figure class="image"><img style="aspect-ratio:629/72;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_14_at_2_38_43_PM_png_0145047a9b.webp" alt="Screenshot 2025-08-14 at 2.38.43 PM.png" width="629" height="72"><figcaption>BIRK sentiment and message volume as of August 14 | Source: Stocktwits</figcaption></figure>Late last month, Goldman Sachs&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-scores-buy-rating-from-goldman-sachs-shares-rise/choGriXR5vX">raised</a> its rating on Birkenstock to ‘Buy’ from ‘Neutral,’ citing "robust" momentum and an attractive valuation for the company's shares in a challenging&nbsp;macroeconomic backdrop.Footwear companies face broad pressure from U.S. import tariffs on major Asian manufacturing hubs, including China and Vietnam.Swiss company On Holding posted strong quarterly sales and raised its full-year target,&nbsp;attributing the increase to recent price increases on its shoes. In the future, CEO Martin Hoffmann&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/on-holding-ceo-martin-hoffmann-says-the-sportswear-maker-is-in-a-good-position-to-digest-tariffs/chrCS0bRd9p">told</a> Stocktwits that the company is now "in a very good position to digest" the tariffs.Birkenstock also raised prices in the U.S. last month.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Various Birkenstock shoes are displayed on shelves in a Birkenstock store on Ehrenstraße. Photo: Rolf Vennenbernd/dpa (Photo by Rolf Vennenbernd/picture alliance via Getty Images)

Why Are Birkenstock Shares Rising Premarket?

The move shows optimism ahead of the German footwear company's quarterly report.

Birkenstock Holding (BIRK) shares rose over 1.5% in Thursday's session and another 2% in extended trading, after Goldman Sachs raised its rating on the sandal maker.The research firm raised the rating on the company's shares to 'Buy' from 'Neutral,' while maintaining its $60 price target, according to a summary of the investor note on The Fly. That indicates an over 15% upside to BIRK's last closing price.Currently, 20 of the 22 analysts covering the stock have a 'Buy' or higher rating, and two rate it 'Hold,' according to Koyfin data. Their average price target is $72.26.Goldman Sachs sees "robust" momentum and an attractive valuation for Birkenstock in a challenging macro backdrop. The company has a "strong" product proposition, with pricing power and opportunities to win share in a "highly fragmented" footwear market, the research firm said.Goldman Sachs also noted Birkenstock's vertically integrated manufacturing setup in Europe, which would support the company's margins.Although&nbsp;<a href="https://stocktwits.com/symbol/BIRK">BIRK shares</a> have rebounded over the last couple of weeks, they remain 15.5% below their 2025 peak achieved on Jan. 30.On Stocktwits, retail sentiment shifted to 'neutral' early Friday from 'bearish' the previous day, with several users&nbsp;taking note of the latest upgrade.<figure class="image"><img style="aspect-ratio:1416/154;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_25_at_10_41_26_AM_png_d52d1b15f5.webp" alt="Screenshot 2025-07-25 at 10.41.26 AM.png" width="1416" height="154"><figcaption>BIRK sentiment and message volume as of July 25 | Source: Stocktwits</figcaption></figure>In May, Birkenstock raised its annual profit outlook and authorized a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-authorizes-200m-buyback-but-retail-remains-cold/ch0AkaLRbti">$200 million share buyback</a>.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/chinese-e-commerce-giant-jd-com-could-reportedly-snap-up-media-markt-parent-for-2-6-b-retail-bulls-eye-breakout/choGqh1R5v9">Chinese E-Commerce Giant JD.com Could Reportedly Snap Up MediaMarkt Parent For $2.6B: Retail Bulls Eye Breakout</a>

A Birkenstock shoe displayed on in a Birkenstock store in North Rhine-Westphalia, Cologne, Germany. (Photo by Rolf Vennenbernd/picture alliance via Getty Images)

Birkenstock Scores 'Buy' Rating From Goldman Sachs, Shares Rise 

The sandal maker has "robust" momentum, attractive valuation, and pricing power, the research firm says.

German sandal&nbsp;maker Birkenstock has filed an infringement lawsuit in India's capital, New Delhi, against four footwear traders, four factories, and two unnamed individuals following a company investigation revealed the production, sale, and export of counterfeit products, according to a Reuters report.The&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/sustainability/boards-policy-regulation/birkenstock-cracks-down-fakes-india-court-ordered-factory-visits-held-sources-2025-07-06/">report</a>, which cites people familiar with the matter,&nbsp;comes as the footwear industry is garnering increased attention in India. Earlier this month, Crocs (CROX) secured a court nod to pursue a nine-year-old infringement case. At the same time,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/prada-credits-centuries-old-indian-kolhapuri-craftsmanship-behind-open-toe-sandals-design-unveiled-at-milan-show/chmZe7GRReZ">Prada drew criticism</a> after its sandals at a Milan showcase looked nearly identical to Indian Khandasari chappals, prompting the Italian fashion brand to acknowledge the similarity.According to the report, Birkenstock filed the lawsuit in the Delhi High Court in May. It claims that Birkenstock counterfeits were being manufactured in rural areas near the North Indian tourist hub of Agra and sold both locally and exported to other countries. The court has ordered law enforcement inspections of these facilities.India is a key market for the German brand, which last month opened its 50th standalone store in the country,&nbsp;in the financial capital of Mumbai.On Stocktwits, the retail sentiment for BIRK remained 'bullish,' unchanged from a week ago.&nbsp;<a href="https://stocktwits.com/symbol/BIRK">Birkenstock shares</a> are down nearly 14% year-to-date.<figure class="image"><img style="aspect-ratio:615/69;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_2_06_14_PM_png_bdebef4034.webp" alt="Screenshot 2025-07-07 at 2.06.14 PM.png" width="615" height="69"><figcaption>BIRK sentiment and message volume as of July 7 | Source: Stocktwits</figcaption></figure>The development comes at a time of strength for the company. It recently reported strong results for its fiscal second quarter,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-raises-annual-profit-forecast-shares-retail-sentiment-surge/chivoCURbnc">raised its annual profit forecast</a>, and authorized a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-authorizes-200m-buyback-but-retail-remains-cold/ch0AkaLRbti">$200 million buyback</a>.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Birkenstock Reportedly Sues Indian Footwear Makers Over Counterfeits Amid Rising Industry Scrutiny

India is a key market for the German brand, which last month opened its 50th standalone store in the country.

Nasdaq-listed shares of argenx SE (ARGX) rose 2% by Friday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://argenx.com/news/2024/argenx-announces-european-commission-approval-of-vyvgart--efgart">announced</a> that the European Commission approved its VYVGART 1,000 mg subcutaneous (SC) injection in the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP).CIDP is a rare and often progressive autoimmune disease of the peripheral nervous system. Patients with CIPD experience a range of mobility and sensory issues, including trouble standing from a seated position, pain and fatigue, and frequent tripping or falling.The European Commission approved the subcutaneous injection as a monotherapy for patients with the disease who have received prior treatment with corticosteroids or immunoglobulins.The EC approval will apply to all 27 European Union Member States, as well as to Iceland, Liechtenstein, and Norway.VYVGART for SC injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. The company stated that it is “working closely” with local regulatory authorities to ensure patients can access the treatment as soon as possible.The approval is based on a clinical trial that demonstrated 66.5% of patients treated with VYVGART SC showed evidence of clinical improvement, including improvements in mobility, function, and strength. The study also revealed a 61% reduction in the risk of relapse compared to the placebo.This regulatory approval marks the second for VYVGART SC in Europe, which first received approval as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.On Stocktwits, retail sentiment around argenx remained within ‘bullish’ territory over the past 24 hours while message volume remained ‘normal’.<figure class="image"><img style="aspect-ratio:631/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_20_at_2_09_51_PM_png_2b09c4d552.webp" alt="ARGX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on June 20, 2025 | Source: Stocktwits" width="631" height="68"><figcaption>ARGX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on June 20, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/ARGX">ARGX stock</a> is down by 12% this year but has gained over 40% in the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-considered-perplexity-acquisition-before-14-3-b-scale-ai-deal/chlxqohRRPz">Meta Reportedly Considered Perplexity Acquisition Before $14.3B Scale AI Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an argenx SE logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease, But Stock Fails To Garner Retail Attention

VYVGART for SC injection is available in vials or prefilled syringes and can be administered by a patient, caregiver, or healthcare professional.

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	N/A
50-Day Moving Average	N/A
Beta	N/A
Avg. Volume	N/A
PE Ratio	N/A

52-Week High	N/A
52-Week Low	N/A
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

SPDW
SPDR Portfolio Developed World ex-US ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SPDW News

SPDWSPDR Portfolio Developed World ex-US ETF